EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Lin Cai, Congjun Jiang, Guoqiang Zhang, Hong Fang, Jinyan Wang, Yumei Li, Hui Xu, Rong Xiao, Yangfeng Ding, Kun Huang, Chunlei Zhang, Litao Zhang und 28 weitere

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae062 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Lin Cai und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Chongqing Genrix Biopharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Xeligekimab (GR1501) is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A and has shown potential efficacy in treating moderate-to-severe psoriasis in preliminary trials.

Objectives

To evaluate the efficacy and safety of xeligekimab in Chinese patients with moderate-to-severe psoriasis.

Methods

A total of 420 Chinese patients were randomized to 200 mg xeligekimab every 2 weeks (n = 281) or placebo (n = 139) for the first 12 weeks, followed by an extension of the treatment schedule to xeligekimab every 4 weeks for a further 40 weeks. Efficacy was assessed by evaluating achievement of Physician Global Assessment (PGA) 0/1 and 75%, 90% and 100% improvement in Psoriasis Area and Severity Index (PASI 75, PASI 90 and PASI 100, respectively). The safety profile was also evaluated.

Results

At week 12, PASI 75, PASI 90 and PASI 100 were achieved in 90.7%, 74.4% and 30.2% of patients in the xeligekimab group vs. 8.6%, 1.4% and 0% of patients in the placebo group, respectively. PGA 0/1 was achieved in 74.4% patients in the xeligekimab group and 3.6% of patients in the placebo group. PASI 75 and PGA 0/1 were maintained until week 52. No unexpected adverse events were recorded.

Conclusions

Xeligekimab showed high efficacy and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedHumansMaleDouble-Blind MethodFemaleMiddle AgedAdultTreatment OutcomeDermatologic AgentsDrug Administration ScheduleInterleukin-17Severity of Illness IndexAgedYoung Adult

Substanzen

Antibodies, Monoclonal, HumanizedDermatologic AgentsInterleukin-17

Autor:innen und Institutionen

  • Department of Dermatology, Peking University People's Hospital, Beijing, China.

ORCID-Profile: Juan Tao

Förderung

  • Chongqing Genrix Biopharmaceutical Co., Ltd

Zitieren

APA

Cai, L., Jiang, C., Zhang, G., Fang, H., Wang, J., Li, Y., Xu, H., Xiao, R., Ding, Y., Huang, K., Zhang, C., Zhang, L., Chen, B., Duan, X., Pan, W., Han, G., Chen, R., Liu, L., Zhang, S., …, & Zhang, J. (2024). A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae062

Vancouver

Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, et al. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae062

BibTeX
@article{Cai2024,
  author = {Cai, Lin and Jiang, Congjun and Zhang, Guoqiang and Fang, Hong and Wang, Jinyan and Li, Yumei and Xu, Hui and Xiao, Rong and Ding, Yangfeng and Huang, Kun and Zhang, Chunlei and Zhang, Litao and Chen, Bin and Duan, Xinsuo and Pan, Weili and Han, Guangming and Chen, Rongyi and Liu, Lunfei and Zhang, Shoumin and Tao, Juan and Pang, Xiaowen and Yu, Jianbin and Wang, Huiping and Zhao, Yi and Li, Chengxin and Kang, Xiaojing and Qin, Lanying and Zhu, Xiaofang and Su, Juan and Li, Shanshan and Yang, Chunjun and Feng, Wenli and Lei, Tiechi and Jiang, Shan and Fang, Ruihua and Lin, Mao and Lu, Qianjin and Xu, Chunxing and Wang, Wei and Zhang, Jianzhong},
  title = {A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae062}
}
Kostenlos starten →